Primer

Decentralized Science (DeSci): Tokenized Funding, Governance, and IP

David Hilmer Rex · July 2026

Summary

Decentralized science applies the tools of crypto, token-based governance, collective treasuries, and tokenized intellectual property, to the funding and ownership of research. It promises permissionless participation: anyone can propose, fund, or govern research without the gatekeeping of grant committees or institutional affiliation. In practice it has concentrated in biotechnology and longevity, run through a small number of platforms, and moved with the crypto market. This primer explains the premise, traces the origins, sets out the building blocks, surveys what DeSci is actually funding, locates it in the wider landscape, and weighs the serious critiques.

The premise ↑

DeSci’s core claim is that research funding and intellectual property are gated by intermediaries, journals, universities, grant committees, and that distributed, token-governed structures can route around them. Funding decisions are made by a community of token-holders rather than a panel. Intellectual property is owned collectively rather than assigned to a university technology-transfer office. In principle this opens participation to patients, amateurs, and global contributors excluded from conventional channels. In practice participation is concentrated in the crypto-native population, which is who holds the tokens.

The tools themselves are not new to science. Blockchains, DAOs, and NFTs predate DeSci; the movement is their application to the specific problem of how research gets funded and who owns the result. Read against the funding-mechanisms primer, DeSci is mainly a new answer to one dial: who decides. The answer is the crowd, weighted by tokens.

Origins ↑

DeSci as a named movement coalesced around 2021. Molecule, a platform for tokenizing biopharma intellectual property, and VitaDAO, a community organised to fund longevity research, together executed what was billed as the first transfer of biopharma IP into an NFT, the mechanism DeSci calls an IP-NFT.¹ Ethereum’s Vitalik Buterin has been an early and visible supporter, and the framing of research as a public good underprovided by markets gave the movement its intellectual footing.

It moved from niche to mainstream crypto attention in late 2024, when DeSci tokens rose sharply, one sector index put the gain at roughly 2,640% over the year, and Buterin and Binance’s Changpeng Zhao appeared at a DeSci event at the Devcon conference in Thailand.² The surge was double-edged. Platforms such as pump.science launched bonding-curve tokens tied to specific compounds, which traded like meme coins and drew speculation alongside the science. The episode is the clearest illustration of the model’s central tension: the same token mechanics that fund research also expose it to the crypto market’s appetites.

The building blocks ↑

Three components recur.

What it's funding ↑

Several thematic DAOs have built real portfolios. VitaDAO (longevity) is the most developed: by early 2024 it had deployed more than US$4 million across some twenty projects, spun out its first company, Matrix Biosciences, from research by the aging biologist Vera Gorbunova, and tokenized IP for others.³ The clearest proof-of-concept came from a project it backed: Gero, an AI-driven company for aging research, signed a partnership with Chugai Pharmaceutical worth up to US$250 million in milestones plus royalties, to develop antibodies against age-related targets identified by Gero’s platform.⁴ Beyond longevity, a cluster of thematic BioDAOs now covers other areas: AthenaDAO (women’s health), ValleyDAO (synthetic biology), HairDAO (hair loss), and CryoDAO (cryopreservation). Commercial validation has continued into 2026: Eli Lilly agreed in April 2026 to acquire CrossBridge Bio, an antibody-drug-conjugate startup the DeSci community counts as ecosystem-funded, for up to US$300 million, though mainstream biotech coverage framed it as a conventional acquisition.⁵

Most activity sits at the earliest, pre-grant stage, seed-funding researchers who cannot yet attract conventional support. The infrastructure has grown accordingly: BIO Protocol’s BIO Genesis raised about US$33 million for a shared treasury, and the network reports directing more than US$50 million to researchers since 2024.⁶ The defining development since 2025 has been a pivot to AI. “BioAgents” are autonomous AI co-scientists meant to generate hypotheses, design experiments, and manage on-chain funding. Aubrai, launched with VitaDAO in August 2025 and trained on the longevity researcher Aubrey de Grey’s lab data, minted more than 1,000 hypotheses on-chain and raised over US$900,000 within weeks.⁷ OpenLabs, launched at DeSci Berlin in June 2026, generalises the model, pairing agents such as RheumaAI (rheumatology) and PeptAI (peptides) with community voting to carry an idea from a post to a funded project.⁸

Where it fits ↑

DeSci is not trying to replace universities or large institutions. It operates at the seed stage and at the periphery of fields where conventional gatekeeping is most acute, which makes it complementary to focused research organisations and enterprise foundations rather than competitive with them. It sits at one end of the funding spectrum, small, fast, permissionless, community-decided, where the enterprise foundations sit at the other, large, patient, and board-governed.

The deeper structural interest is that a research DAO is a self-owning institution: it owns itself, encodes its rules in advance, and is built to outlast its founders. That places it in a long lineage of ownerless institutions, the charitable trust, the endowment, the enterprise foundation, whose durability came from legal entrenchment and human judgment rather than code. DeSci is the digital-native attempt at the same idea, and its strengths and weaknesses are largely the mirror image of the foundation’s.

Critiques and open questions ↑

The objections are serious.

Coupling to the crypto market. Token-denominated treasuries rise and fall with crypto prices, so research funding is exposed to conditions that have nothing to do with the science. The 2024 surge and the meme-token dynamics around pump.science showed how quickly the incentive can tip from funding research to trading it. The boom-and-bust is now well documented: BIO Protocol fell from an all-time high near US$0.88 in January 2025 to around US$0.018 by March 2026, a drawdown of more than 90%, before a sharp partial rebound that April. By mid-2026 the sector’s market capitalisation had settled around US$260 million, and observers described the year as one of consolidation rather than hype.⁹

Governance at scale. Token-weighted voting concentrates influence in large holders and struggles to make expert judgments about which research to fund without professional management, reproducing the gatekeeping DeSci set out to remove, only with different gatekeepers.

Regulatory exposure. This is the most underappreciated risk. Tokenized IP in biotech sits at an uncomfortable intersection of securities law (is the token a financial instrument?), patent law (does tokenization affect assignment or licensing chains?), and pharmaceutical regulation (does a DAO constitute a drug sponsor?). None of these questions are resolved in most jurisdictions, and the DeSci community tends to underplay them.

Concentration. The portfolio is heavily weighted toward biotechnology and longevity, the fields where token-holders’ personal interest and willingness to fund are highest. That is a narrow slice of what science needs.

Whether DeSci matures into durable research infrastructure or remains a niche experiment tied to the crypto cycle is genuinely open. The proof-of-concept deals are real; so is the dependence on a volatile market and an unresolved legal footing.